ClinicalTrials.gg
AvailableNCT03576690Updated Oct 9, 2026

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

An expanded access record providing REGN3470-3471-3479 in Ebola Virus Disease, sponsored by Regeneron Pharmaceuticals. Available. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Regeneron Pharmaceuticals · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Sex
All
01

Study summary

Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).

02

Conditions studied

  • Ebola Virus Disease

Keywords

  • Positive Ebola Virus (EBOV) diagnostic test
  • symptomatic
03

In context

Hemorrhagic Fever, Ebola

104 studies on the registry are indexed under Hemorrhagic Fever, Ebola; 13 are open to participants now.

Browse Hemorrhagic Fever, Ebola studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Eligibility criteria

Key Inclusion Criteria:

  • Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic
  • Ability to provide personally or by a legal representative if the patient is unable to do so, based on local laws and regulations
  • REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol
  • Children of any age will be eligible for enrollment, as defined in the protocol
  • Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol

Key Exclusion Criteria:

  • Negative EBOV diagnostic test result
  • A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
  • Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions
  • Eligible for an ongoing randomized clinical trial with REGN-EB3

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • BiologicalREGN3470-3471-3479

    Also known as: REGN-EB3, Inmazeb®, atoltivimab, maftivimab, and odesivimab

06

Where to request access

No study locations are listed for this record.

07

Updates

1 registry update since Sep 25, 2026
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

08

Registry details

Key details

Study ID
NCT03576690
Responsible party
Sponsor
First posted
Jul 3, 2018
Last update
Oct 9, 2026

Study contacts

Requests for compassionate use must be initiated by a treating physician. Physicians should contact
Contact
compassionateuserequests@regeneron.com
844-734-6643
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion